文献速递冠心病

急性冠脉综合征患者非罪犯冠脉斑块的管理

Management of non-culprit coronary plaques in patients with acute coronary syndrome.
PubMed 文献 · Eur Heart J · 2020-01-01

约50%的STEMI患者存在多支冠脉病变,与复发性缺血事件和死亡率增加相关。基于近期证据,对阻塞性非罪犯病变行分期PCI应视为这些患者管理的金标准,但分期PCI最佳时机、中间型非罪犯病变的评估及易损斑块预防性干预的价值仍不明确。本综述讨论STEMI患者非罪犯斑块管理的新概念,提出诊断和治疗流程以指导临床实践,并指出未来研究需解决的知识空白。

要点

  • 约50%的STEMI患者存在多支冠脉病变,与复发性缺血事件和死亡率增加相关。
  • 对阻塞性非罪犯病变行分期PCI应视为这些患者管理的金标准,但最佳时机未完全确定。
  • 压力导丝指标似乎不能正确识别可安全推迟干预的中间型非罪犯病变患者。

核心结论

  • 对阻塞性非罪犯病变行分期PCI应视为STEMI合并多支病变患者管理的金标准。
  • 分期PCI最佳时机、中间型非罪犯病变评估及易损斑块预防性PCI或强化药物治疗的临床获益尚不明确。

研究设计与样本

  • 综述,讨论STEMI患者非罪犯斑块管理的最新概念,并提出诊断和治疗流程。

主要发现

  • 约50%的STEMI患者存在多支冠脉病变,与复发性缺血事件发生率增加和死亡率更高相关。
  • 压力导丝指标似乎不能正确识别可安全推迟干预的中间型非罪犯病变患者。
  • 冠脉内成像可能有助于识别含易损斑块且未来心血管事件风险更高的未处理非罪犯病变。
  • 迄今尚无研究证明对易损斑块行预防性PCI或更强化药物治疗与临床结局改善相关。

临床怎么用

  • 对STEMI患者的阻塞性非罪犯病变应考虑分期PCI。
  • 中间型非罪犯病变可借助冠脉内成像识别易损斑块,辅助风险分层。
  • 易损斑块的预防性PCI或强化药物治疗尚缺乏临床结局改善证据,需个体化决策。

局限性

  • 分期PCI最佳时机未完全确定。
  • 压力导丝指标对中间型非罪犯病变推迟干预的安全性识别能力不足。
  • 缺乏预防性PCI或强化药物治疗改善临床结局的研究证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 50% of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease, a condition associated with an increased incidence of recurrent ischaemic events and higher mortality. Based on recent evidences, a strategy of staged percutaneous coronary intervention (PCI) of obstructive non-culprit lesions should be considered the gold standard for the management of these patients. However, several issues remain still unresolved. Indeed, what is the optimal timing of staged PCI is not completely defined. Moreover, assessment of intermediate non-culprit lesions represent still a clinical conundrum, as pressure-wire indexes do not seem able to correctly identify those patients in whom deferral is safe. Intracoronary imaging may help to identify untreated non-culprit lesions containing vulnerable plaques that may portend a higher risk of future cardiovascular events. However, there are hitherto no studies demonstrating that preventive PCI of vulnerable plaques or more intensive pharmacological treatment is associated with an improved clinical outcome. In this review, we discuss the recent evolving concepts about management of non-culprit plaques in STEMI patients, proposing a diagnostic and therapeutic algorithm to guide physicians in clinical practice. We also underscore the several knowledge gaps to address in future studies.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Montone RA, Niccoli G, Crea F, et al. Management of non-culprit coronary plaques in patients with acute coronary syndrome. Eur Heart J. 2020. PMID: 32676644. doi:10.1093/eurheartj/ehaa481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。